Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.72 |
| ▸ | PREP | P48147 | 4/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16192794 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL961190 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL3460435 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL1034394 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL8011988 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL25247226 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL961189 | 1.00 | CHRM2 (0.72) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| Acetic Acid SCHEMBL30147258 | 0.95 | CHRM2 (0.66) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL8185274 | 0.93 | CHRM2 (0.63) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL17593204 | 0.93 | CHRM2 (0.63) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3569604-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-7728006-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070281970-A1 | Quinolinone-Carboxamide Compounds as 5-Ht4 Receptor Agonists | ALFASIGMA S.P.A. (IT) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281970-A1 | Quinolinone-Carboxamide Compounds as 5-Ht4 Receptor Agonists | HTR4, HTR7, HTR3C | CHRM2 143/4885CHRM1 119/4885CHRM3 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.